BridgeBio Pharma, Inc.
DE ˙ MUN ˙ US10806X1028
56,19 € ↓ -1,02 (-1,78%)
2026-06-01
CENA AKCJI
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership1,908,907 shares
Latest Disclosed Value $ 146,012,296
Alliancebernstein L.p. reports 6.92% decrease in ownership of 2CL / BridgeBio Pharma, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 1,908,907 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $119,955,716 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 2,050,746 shares of BridgeBio Pharma, Inc.. This represents a change in shares of -6.92% during the quarter. The current value of the position is $107,261,484 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,908,907 -141,839 -6.92 146,012 -6.92 0.0473
2026-02-17 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,050,746 -277,969 -11.94 156,862 29.69 0.0495
2025-11-14 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 2,328,715 -141,843 -5.74 120,953 13.38 0.0381
2025-08-14 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 2,470,558 -213,588 -7.96 106,679 14.97 0.0348
2025-05-15 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,684,146 -110,146 -3.94 92,791 21.02 0.0336
2025-02-12 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,794,292 -33,374 -1.18 76,675 6.50 0.0260
2024-11-14 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 2,827,666 375,262 15.30 71,992 15.89 0.0242
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 2,452,404 -391,895 -13.78 62,119 -29.37 0.0217
2024-05-14 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,844,299 286,883 11.22 87,946 -14.82 0.0311
2024-02-14 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,557,416 -158,724 -5.84 103,243 44.14 0.0397
2023-11-14 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 2,716,140 2,560,549 1,645.69 71,625 2,576.53 0.0305
2023-08-15 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 155,591 22,833 17.20 2,676 21.58 0.0011
2023-05-15 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 132,758 -200 -0.15 2,201 117.28 0.0009
2023-02-15 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 132,958 0 0.00 1,013 -23.37 0.0005
2022-11-15 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 132,958 -185,258 -58.22 1,322 -54.24 0.0006
2022-08-15 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 318,216 -38,516 -10.80 2,889 -20.22 0.0013
2022-05-13 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 356,732 -60,198 -14.44 3,621 -47.93 0.0014
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 416,930 279,232 202.79 6,954 7.75 0.0025
2021-11-10 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 137,698 1,750 1.29 6,454 -22.12 0.0025
2021-07-30 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 135,948 -2,410 -1.74 8,287 -2.77 0.0033
2021-05-06 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 138,358 34,374 33.06 8,523 15.27 0.0037
2021-02-08 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 103,984 0 0.00 7,394 89.54 0.0035
2020-11-12 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 103,984 -2,433 -2.29 3,901 12.42 0.0021
2020-08-13 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 106,417 6,800 6.83 3,470 20.11 0.0020
2020-05-14 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 99,617 72,164 262.86 2,889 200.31 0.0021
2020-02-18 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 27,453 27,453 962 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.